In the spring of 2018, NCATS issued one bench-to-clinic award. The funded pre-clinical project serves as a “use case” to demonstrate the utility of an independent crowdsourcing effort or a computational algorithm to predict new therapeutic uses of an existing drug or biologic. View the project below:
Repurposing Misoprostol to Prevent Recurrence of Clostridium Difficile Infection
Vanderbilt University Medical Center, Washington University School of Medicine and University of North Carolina at Chapel Hill
Principal Investigators: David M. Aronoff, M.D. (Vanderbilt), Erik R. Dubberke, M.D. (WUSTL), and Sarah McGill, M.D. (UNC)
Grant Number: 1-U01TR002398-01
The bacterium Clostridium difficile is a major cause of antibiotic-associated diarrhea and a leading infectious disease in U.S. hospitals. The infection can recur multiple times despite initially adequate treatment. This project builds on the results of studies that demonstrated a possible new therapeutic use for misoprostol, a drug approved by the Food and Drug Administration to treat certain types of ulcers, in preventing or treating C. difficile colitis. This team will conduct a clinical trial to test the hypothesis that patients with a primary episode of C. difficile infection who are treated with misoprostol in addition to standard therapy will have a reduced rate of C. difficile infection recurrence compared to patients receiving standard care only.